In re Aimmune Therapeutics, Inc. Securities Litigation (Aimmune Merger), No.  3:209-CV-06733-MMC (N.D.Ca.). On July 18, 2025, after more than four years of litigation, the Hon. Maxine Chesney entered a Final Judgment approving a $27.5 million settlement for the Class in a Class action for breach of fiduciary duties to shareholders relating to the merger )tender offer) of the biomedical company Aimmune Therapeutics – which settled just two months from trial.